logo
  • About us
  • Pipeline
    • AT-001
    • AT-002
    • AT-003
    • AT-004
    • SYN-001
  • Science
  • Team
  • The Pulse
LinkedIn Partner with us
  • Home
  • About us
  • Pipeline
    • AT-001
    • AT-002
    • AT-003
    • AT-004
    • SYN-001
  • Science
  • Team
  • The Pulse
  • Contact us
Arctic Therapeutics Financing 1200 X 630 V 2
Latest news

Arctic Therapeutics Closes Oversubscribed $21.5M Financing

Arctic Therapeutics (ATx), a clinical-stage biopharmaceutical company translating genetic discoveries into new treatments for diseases with significant unmet medical need, today announced the closing of an oversubscribed $21.5…

Read Article
A Consortium Including Arctic Therapeutics Launches Synaptiq with Acquisition of Clinical-Stage SYN-001 Program
News

A Consortium Including Arctic Therapeutics Launches Synaptiq with Acquisition of Clinical-Stage SYN-001 Program

Arctic Therapeutics Announces Enrollment of First Patients in Phase IIa Trial of AT-004 for Acne Vulgaris
News

Arctic Therapeutics Announces Enrollment of First Patients in Phase IIa Trial of AT-004 for Acne Vulgaris

Arctic Therapeutics Receives EMA Approval for Phase IIa Study of AT-001 in Alzheimer’s Disease
News

Arctic Therapeutics Receives EMA Approval for Phase IIa Study of AT-001 in Alzheimer’s Disease

The Global Burden of Atopic Dermatitis: What the Numbers Reveal
Insights

The Global Burden of Atopic Dermatitis: What the Numbers Reveal

Multiple cross-sectional CT scan images of a human brain arranged in a grid, showing horizontal and coronal views in blue and white tones for diagnostic analysis.
Insights

CLEC16A: The Gene at the Crossroads of Immunity and Neurodegeneration

Psoriasis Is More Than Skin Deep: Systemic Inflammation and Comorbidities
Insights

Psoriasis Is More Than Skin Deep: Systemic Inflammation and Comorbidities

Fujirebio’s FDA-Approved Alzheimer’s Blood Test Hailed as ‘Game Changer’
Insights

Fujirebio’s FDA-Approved Alzheimer’s Blood Test Hailed as ‘Game Changer’

Arctic Therapeutics Research Suggests Preventative Strategy Against HCCAA
News

Arctic Therapeutics Research Suggests Preventative Strategy Against HCCAA

Arctic Therapeutics Announces €26.5M Oversubscribed Series A Financing
News

Arctic Therapeutics Announces €26.5M Oversubscribed Series A Financing

Upcoming Events

  • 26 Nov

    November 26th 2026

    World Congress on Clinical & Experimental Dermatology

Envelope

Keep an eye on the pulse

Sign up to receive the latest news on Arctic Therapeutics and the latest industry trends.




    Arctic Therapeutics

    Locations

    Our clinical operation is located in Akureyri in the north of Iceland, supported by commercial operations in Reykjavik and Philadelphia, PA.

    Mailing address

    Commercial:
    Gróska Innovation Center
    Kristínargata 1, 102 Reykjavik
    Clinical Operations:
    Drift EA, Strandgata 1, 600 Akureyri

    Contact

    • Partner with us
    • Join our team
    • Interested investors
    • Everything else

    Navigation

    • About us
    • Pipeline
    • Our Science
    • Team
    • The Pulse
    At Ackrediteringssymbol 10530 Ss En Iso 15189 2022

     

    LinkedIn
    Legal disclaimer – Privacy policy
    Feedback & Complaints
    Synaptiq Therapeutics

    Contact

    • Partner with us
    • Join our team
    • Interested investors
    • Everything else

    Mailing address

    Strandgata 1, 600 Akureyri

    LinkedIn

    Copyright © 2026 – Arctic Therapeutics